TNFR2缺失通过下调淋巴结特定树突状细胞群并抑制IL-23/IL-17通路减轻小鼠银屑病炎症
该研究在咪喹莫特银屑病小鼠模型中发现,Tnfr2敲除而非Tnfr1敲除可显著减轻表皮增生、特征性皮损及IL-23或IL-17A水平。咪喹莫特介导的引流淋巴结髓系树突状细胞、产TNF/诱导型一氧化氮合酶树突状细胞及IL-23表达增加依赖TNFR2而非TNFR1。结果支持银屑病炎症不依赖TNFR1活性,而由TNFR2依赖的IL-23/IL-17通路激活驱动,靶向TNFR2通路可能成为银屑病潜在下一代治疗方向。
要点
- Tnfr2敲除小鼠在咪喹莫特模型中银屑病皮损显著减轻,Tnfr1敲除小鼠无此减轻。
- 引流淋巴结髓系树突状细胞、产TNF/iNOS树突状细胞及IL-23增加依赖TNFR2而非TNFR1。
- 银屑病炎症不依赖TNFR1活性,由TNFR2依赖的IL-23/IL-17通路激活驱动。
核心结论
- 银屑病炎症不依赖TNFR1活性,而由TNFR2依赖的IL-23/IL-17通路激活驱动。
- 靶向TNFR2通路可能成为银屑病潜在下一代治疗方向。
研究设计与样本
- 在咪喹莫特银屑病模型中比较Tnfr2敲除与Tnfr1敲除小鼠。
主要发现
- Tnfr2敲除小鼠表皮增生、特征性大体皮损及IL-23或IL-17A水平显著降低,Tnfr1敲除小鼠未见降低。
- 咪喹莫特介导的引流淋巴结髓系树突状细胞增加依赖TNFR2而非TNFR1。
- 咪喹莫特介导的引流淋巴结产TNF/诱导型一氧化氮合酶树突状细胞增加依赖TNFR2而非TNFR1。
- 咪喹莫特介导的引流淋巴结IL-23表达增加依赖TNFR2而非TNFR1。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TNF-α, a proinflammatory cytokine, is a crucial mediator of psoriasis pathogenesis. TNF-α functions by activating TNFR1 and TNFR2. Anti-TNF drugs that neutralize TNF-α, thus blocking the activation of TNFR1 and TNFR2, have been proven highly therapeutic in psoriatic diseases. TNF-α also plays an important role in host defense; thus, anti-TNF therapy can cause potentially serious adverse effects, including opportunistic infections and latent tuberculosis reactivation. These adverse effects are attributed to TNFR1 inactivation. Therefore, understanding the relative contributions of TNFR1 and TNFR2 has clinical implications in mitigating psoriasis versus global TNF-α blockade. We found a significant reduction in psoriasis lesions as measured by epidermal hyperplasia, characteristic gross skin lesion, and IL-23 or IL-17A levels in Tnfr2-knockout but not in Tnfr1-knockout mice in the imiquimod psoriasis model. Furthermore, imiquimod-mediated increase in the myeloid dendritic cells, TNF/inducible nitric oxide synthase‒producing dendritic cells, and IL-23 expression in the draining lymph nodes were dependent on TNFR2 but not on TNFR1. Together, our results support that psoriatic inflammation is not dependent on TNFR1 activity but is driven by a TNFR2-dependent IL-23/IL-17 pathway activation. Thus, targeting the TNFR2 pathway may emerge as a potential next-generation therapeutic approach for psoriatic diseases.
引用
- Chandrasekharan UM, Kaur R, Harvey JE, et al. TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways. J Invest Dermatol. 2022. PMID: 35090950. doi:10.1016/j.jid.2021.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。